Initial voriconazole trough blood levels and clinical outcomes of invasive aspergillosis in patients with hematologic malignancies.

There are limited data on the relationship between voriconazole levels and clinical outcomes relative to invasive aspergillosis (IA). We therefore analyzed the association between initial voriconazole trough blood levels and clinical responses of IA in patients with hematologic malignancies. All adult patients treated with voriconazole in a tertiary care hospital in Seoul, South Korea, between August 2009 and April 2011 were identified from pharmacy records. Initial voriconazole trough levels were routinely measured 1 week after therapy and patient responses were classified as success (complete or partial response) or failure (stable response, progression of disease, or death) at 2 weeks post-therapy. Fifty-two patients, involving 2 (4%) proven, 29 (56%) probable, and 21 (40%) possible IA infections, were included. Of these, 11 (21%) had initial voriconazole levels of ≤ 2 mg/l and the remaining 41 (79%) had > 2 mg/l. There were slightly fewer successful responses (45%, 5/11) in the patients with initial voriconazole levels ≤ 2 mg/l than in those with voriconazole levels > 2 mg/l (51%, 21/41), but the difference was not statistically significant (P= 0.73). Neutropenia (OR 0.1, P= 0.008) and immunosuppression (OR 0.1, P= 0.004) were independently associated with 2-week successful response after voriconazole therapy. In conclusion, initial voriconazole trough levels may not significantly affect clinical outcomes of IA at 2 weeks after voriconazole therapy in patients with hematologic malignancies. Further studies of prospective design are needed to establish the optimal procedure for voriconazole drug monitoring.

[1]  S. Kim,et al.  Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea , 2011, The Korean journal of internal medicine.

[2]  D. Marriott,et al.  Voriconazole concentrations and outcome of invasive fungal infections. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  M. Xavier,et al.  Voriconazole therapeutic drug monitoring: focus on safety , 2010, Expert opinion on drug safety.

[4]  W. Haefeli,et al.  Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. , 2009, British journal of clinical pharmacology.

[5]  M. Kurokawa,et al.  Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders , 2009, International journal of hematology.

[6]  J. Mehta,et al.  Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation , 2009, Antimicrobial Agents and Chemotherapy.

[7]  J. Perfect,et al.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Thierry Buclin,et al.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  L. Gordon,et al.  Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients , 2007, Cancer.

[11]  M. Boeckh,et al.  Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Mehta,et al.  Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients , 2005, Bone Marrow Transplantation.

[13]  C. A. Kauffman,et al.  Voriconazole: a new triazole antifungal agent. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  E. Thiel,et al.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  S. Higuchi,et al.  Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. , 1998, Therapeutic drug monitoring.

[16]  J. Wilt,et al.  Medical Mycology , 1944, Nature.